JP2023548657A5 - - Google Patents
Info
- Publication number
- JP2023548657A5 JP2023548657A5 JP2023521702A JP2023521702A JP2023548657A5 JP 2023548657 A5 JP2023548657 A5 JP 2023548657A5 JP 2023521702 A JP2023521702 A JP 2023521702A JP 2023521702 A JP2023521702 A JP 2023521702A JP 2023548657 A5 JP2023548657 A5 JP 2023548657A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089965P | 2020-10-09 | 2020-10-09 | |
| US63/089,965 | 2020-10-09 | ||
| US202163151468P | 2021-02-19 | 2021-02-19 | |
| US63/151,468 | 2021-02-19 | ||
| PCT/US2021/054191 WO2022076831A2 (en) | 2020-10-09 | 2021-10-08 | Methods for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023548657A JP2023548657A (ja) | 2023-11-20 |
| JPWO2022076831A5 JPWO2022076831A5 (https=) | 2024-10-15 |
| JP2023548657A5 true JP2023548657A5 (https=) | 2024-10-15 |
Family
ID=78516928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023521702A Pending JP2023548657A (ja) | 2020-10-09 | 2021-10-08 | がんの処置に使用するための、ｅｇｆｒおよび／またはｈｅｒ２のヘテロ環阻害剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240101576A1 (https=) |
| EP (1) | EP4225445A2 (https=) |
| JP (1) | JP2023548657A (https=) |
| KR (1) | KR20230107419A (https=) |
| AU (1) | AU2021358596A1 (https=) |
| BR (1) | BR112023006531A2 (https=) |
| CA (1) | CA3198202A1 (https=) |
| CL (2) | CL2023001012A1 (https=) |
| IL (1) | IL301929A (https=) |
| MX (1) | MX2023004085A (https=) |
| PH (1) | PH12023500010A1 (https=) |
| TW (1) | TW202227063A (https=) |
| WO (1) | WO2022076831A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| EP4323356A1 (en) | 2021-04-13 | 2024-02-21 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| IL321504A (en) * | 2022-12-23 | 2025-08-01 | Tay Therapeutics Ltd | Selective beta inhibitors and their uses |
| CN115819418B (zh) * | 2023-02-14 | 2023-04-28 | 山东绿叶制药有限公司 | Plk1激酶抑制剂及其制备方法和应用 |
| CN121909190A (zh) * | 2023-06-08 | 2026-04-21 | 安塔列斯疗法股份有限公司 | 1,5-二氢-4H-吡咯并[3,2-c]吡啶-4-酮用于癌症治疗 |
| CN121712773A (zh) | 2023-06-08 | 2026-03-20 | 安塔列斯疗法股份有限公司 | 1,5-二氢-4h-吡咯并[3,2-c]吡啶-4-酮用于癌症治疗 |
| CN119528906A (zh) * | 2023-08-30 | 2025-02-28 | 中国科学院上海药物研究所 | 氮杂螺环类化合物及其制备方法、药物组合物和应用 |
| EP4534085A1 (en) * | 2023-10-03 | 2025-04-09 | Scorpion Therapeutics, Inc. | Compounds for use in methods of treating cancer |
| WO2025251058A1 (en) * | 2024-05-31 | 2025-12-04 | Celyn Therapeutics, Inc. | Egfr inhibitors in cancer treatment |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6906194B2 (en) | 2003-10-08 | 2005-06-14 | Massachusetts Instititue Of Technology | Fluorescence assay for kinase activity |
| US7964729B2 (en) | 2006-08-28 | 2011-06-21 | Massachusetts Institute Of Technology | Sox-based kinase sensor |
| ES2570756T3 (es) * | 2009-06-15 | 2016-05-20 | Nerviano Medical Sciences Srl | Derivados pirimidinilpirrolopiridinona sustituidos, proceso para su preparación y su uso como inhibidores de cinasa |
| JP5825932B2 (ja) | 2011-08-26 | 2015-12-02 | キヤノン株式会社 | 撮像装置及びその制御方法、プログラム、及び記録媒体 |
| WO2013092512A1 (en) | 2011-12-21 | 2013-06-27 | Bayer Intellectual Property Gmbh | Substituted benzylpyrazoles |
| WO2013167698A1 (en) | 2012-05-11 | 2013-11-14 | Bayer Pharma Aktiengesellschaft | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer |
| EP2976335A1 (en) | 2013-03-21 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted indazoles |
| EP2976336A1 (en) | 2013-03-21 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | 3-heteroaryl substituted indazoles |
| CN105452237A (zh) | 2013-06-21 | 2016-03-30 | 拜耳制药股份公司 | 杂芳基取代的吡唑 |
| JP2016525076A (ja) | 2013-06-21 | 2016-08-22 | バイエル ファーマ アクチエンゲゼルシャフト | 置換されたベンジルピラゾール類 |
| WO2014202588A1 (en) | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| JP2016526540A (ja) | 2013-06-21 | 2016-09-05 | バイエル ファーマ アクチエンゲゼルシャフト | 置換ベンジルピラゾール |
| CA2928998A1 (en) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| EP3143015B1 (en) | 2014-05-13 | 2019-02-20 | ARIAD Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| AR100886A1 (es) | 2014-06-17 | 2016-11-09 | Bayer Pharma AG | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas |
| AU2016212230B2 (en) * | 2015-01-28 | 2019-09-19 | Bayer Pharma Aktiengesellschaft | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives |
| CA2989469A1 (en) | 2015-06-17 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones |
| US10308629B2 (en) | 2015-08-05 | 2019-06-04 | Bayer Pharma Aktiengesellschaft | 1H-pyrrol-3-amines |
| BR112018004175B8 (pt) | 2015-09-01 | 2023-10-31 | Taiho Pharmaceutical Co Ltd | Composto pirazolo[3,4-d]pirimidina, composição farmacêutica e usos terapêuticos do dito composto |
| US11339157B1 (en) * | 2017-10-24 | 2022-05-24 | Bayer Aktiengesellschaft | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives |
| CA3091834A1 (en) | 2018-02-23 | 2019-08-29 | The Regents Of The University Of Michigan | Egfr dimer disruptors and use of the same |
| WO2019241715A1 (en) | 2018-06-14 | 2019-12-19 | Dana-Farber Cancer Institute, Inc. | Cyano quinoline amide compounds as her2 inhibitors and methods of use |
| WO2019246541A1 (en) | 2018-06-21 | 2019-12-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of egfr and methods of use thereof |
| CA3128946A1 (en) * | 2019-02-07 | 2020-08-13 | Bayer Aktiengesellschaft | 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors |
-
2021
- 2021-10-08 BR BR112023006531A patent/BR112023006531A2/pt unknown
- 2021-10-08 TW TW110137651A patent/TW202227063A/zh unknown
- 2021-10-08 US US18/030,211 patent/US20240101576A1/en active Pending
- 2021-10-08 KR KR1020237015734A patent/KR20230107419A/ko active Pending
- 2021-10-08 IL IL301929A patent/IL301929A/en unknown
- 2021-10-08 PH PH1/2023/500010A patent/PH12023500010A1/en unknown
- 2021-10-08 JP JP2023521702A patent/JP2023548657A/ja active Pending
- 2021-10-08 AU AU2021358596A patent/AU2021358596A1/en active Pending
- 2021-10-08 WO PCT/US2021/054191 patent/WO2022076831A2/en not_active Ceased
- 2021-10-08 CA CA3198202A patent/CA3198202A1/en active Pending
- 2021-10-08 MX MX2023004085A patent/MX2023004085A/es unknown
- 2021-10-08 EP EP21802493.3A patent/EP4225445A2/en active Pending
-
2023
- 2023-04-06 CL CL2023001012A patent/CL2023001012A1/es unknown
-
2025
- 2025-12-22 CL CL2025004052A patent/CL2025004052A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2025004052A1 (es) | Derivados pirazolo[3,2-c]piridinona, inhibidores egfr y/o her2; composición; uso en cáncer | |
| JP2023548657A5 (https=) | ||
| CN305868811S (https=) | ||
| CN305529155S (https=) | ||
| CN305535440S (https=) | ||
| CN305534633S (https=) | ||
| CN305635904S (https=) | ||
| CN305534369S (https=) | ||
| CN305531310S (https=) | ||
| CN305608384S (https=) | ||
| CN305529513S (https=) | ||
| CN305608358S (https=) | ||
| CN305860261S (https=) | ||
| CN305528752S (https=) | ||
| CN305604784S (https=) | ||
| CN305528141S (https=) | ||
| BY20200332A (https=) | ||
| CN305582798S (https=) | ||
| CN306624123S (https=) | ||
| CN305579913S (https=) | ||
| CN305698797S (https=) | ||
| CN305929615S (https=) | ||
| CN305926919S (https=) | ||
| CN305926493S (https=) | ||
| CN305924188S (https=) |